Daltroban

Drug Profile

Daltroban

Alternative Names: BM 13505; SKF 96148

Latest Information Update: 06 Oct 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer GlaxoSmithKline; Roche
  • Class Anti-ischaemics; Antiplatelets; Immunotherapies; Phenylacetates; Small molecules; Sulfonamides; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 06 Oct 1997 Discontinued-III for Ischaemic heart disorders (PO)
  • 06 Oct 1997 Discontinued-III for Thrombosis in Germany (PO)
  • 06 Oct 1997 Discontinued-III for Thrombosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top